ArticleWorld journal of psychiatry2020
Serum levels of chemokines in adolescents with major depression treated with fluoxetine.
Article in World journal of psychiatry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 22 citations in OpenAlex.
- Integrative In Silico Analysis of miRNA-mRNA Regulatory Networks in the Prefrontal Cortex of Individuals with Psychiatric Disorders Who Died by Suicide.International journal of molecular sciences · 2026Article
- Isomeric 3-Pyridinylmethylcoumarins Differ in Erk1/2-Inhibition and Modulation of BV2 Microglia-Mediated Neuroinflammation.Molecules (Basel, Switzerland) · 2025Article
- Alterations in fecal microbiota composition and cytokine expression profiles in adolescents with depression: a case-control study.Scientific reports · 2025Article
- Article
- Transdiagnostic Associations between Anger Hostility and Chemokine Interferon-gamma Inducible Protein 10.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2024Article
- Proteomic profiles of cytokines and chemokines in moderate to severe depression: Implications for comorbidities and biomarker discovery.Brain, behavior, & immunity - health · 2024Article
- Decreased IL-4 is the risk factor of depression in patients with Takayasu arteritis.Frontiers in medicine · 2024Article
- Biomarkers associated with treatment outcome in young people with depression: A systematic review.Neuroscience applied · 2024Review
- Upregulation of S100A8 in peripheral blood mononuclear cells from patients with depression treated with SSRIs: a pilot study.Proteome science · 2023Article
- Correlation analysis of monocyte chemoattractant protein-1 and clinical characteristics and cognitive impairment in type 2 diabetes mellitus comorbid major depressive disorder.Frontiers in aging neuroscience · 2023Article
- Article
- A Preliminary Study of Proinflammatory Cytokines and Depression Following West Nile Virus Infection.Pathogens (Basel, Switzerland) · 2022Article
- Changes in the amplitude of low-frequency fluctuations in specific frequency bands in major depressive disorder after electroconvulsive therapy.World journal of psychiatry · 2022Article
- Article
- Screening of SERT and p11 mRNA Levels in Airline Pilots: A Translational Approach.Frontiers in psychiatry · 2022Article
- Higher fasting C-peptide is associated with post-stroke depression: a multicenter prospective cohort study.BMC neurology · 2021Article
- On inflammatory hypothesis of depression: what is the role of IL-6 in the middle of the chaos?Journal of neuroinflammation · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMajor depressive disorder (MDD) is a global health issue that affects 350 million people of all ages. Although between 2% and 5.6% of affected individuals are adolescents, research on young patients is limited. The inflammatory response contributes to the onset of depression, and in adult MDD patients, symptom severity has been linked to chemokine levels.
aimTo determine the differences in circulatory levels of chemokines in healthy volunteers (HVs) and adolescents with MDD, and assess the changes induced by fluoxetine consume.
methodsThe 22 adolescents with MDD were monitored during the first 8 wk of clinical follow-up and clinical psychiatric evaluation was done using the Hamilton depresión rating scale (HDRS). The serum levels of monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein (MIP)-1α, MIP-1β, interleukin (IL)-8, interferon gamma-induced protein (IP)-10, and eotaxin were measured in patients and HVs.
resultsIn all cases, significant differences were detected in circulating chemokine levels between patients before treatment and HVs (
conclusionDespite the consumption of fluoxetine, patients had significantly higher chemokine levels, even after considering the improvement in HDRS score. The high levels of eotaxin, IP-10, and IL-8 partially explain certain aspects that are affected in MDD such as cognition, memory, and learning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.